Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.
About CLS-1: Treatment of obesity via modulation of chemical signaling relating to gut microbiota
Under the recently-announced microbiota modulation platform operated by Aptorum Group’s wholly-owned subsidiary Claves Life Sciences Limited, we have commenced the preclinical development of macromolecule candidate CLS-1 targeting the treatment of obesity. CLS-1 is undergoing lead optimization and is expected to progress into the IND enabling stage in 2020.
The prevalence of obesity continues to escalate globally; however, there is no current optimal therapy for this condition1. For the majority of obese patients, conventional medical therapies (i.e., diet, exercise, behavioral counseling) often have a high failure rate for the long term2. We believe current pharmacotherapy has limited efficacy and is associated with substantial safety issues, and this will provide immeasurable market opportunity for CLS-1.
Chemical signaling of gut microbiota is known to be one of the major causes of obesity1. CLS-1 is an orally administered non-absorbable macromolecule that modulates the metabolite excreted by gut microbiota with high affinity and specificity. In this way, we believe the absorption of this particular metabolite, which is linked to obesity, can be inhibited.
Aptorum Group is also pursuing two further indications based on the modulation of microbiota based chemical signaling involving the above large molecule technology, which we believe to be highly scalable and we hope to be making further announcements regarding our efforts in due course.
About SACT-1: Repurposed Drug Candidates for the Treatment of Neuroblastoma
Under the recently announced Smart-ACTTM computational drug discovery platform operated by our wholly-owned subsidiary Smart Pharma Group, Aptorum Group has completed computational screening of approximately 1,615 marketed drugs against 3 therapeutic target proteins to potentially tackle poor prognosis of neuroblastoma, i.e., a rare type of children’s cancer that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, especially in children3. For the high-risk group, the 5-year survival rate of this condition is around 40-50% as observed by the American Cancer Society.4 Aptorum Group has identified an array of repurposed candidates and has proceeded to evaluate them in cell-based and animal models in order to validate the candidates’ usage for such new indication and potential efficacies.
Aptorum Group is also pursuing two further indications under the Smart-ACTTM drug discovery platform and hopes to be making further announcements regarding our research in due course.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics subsidiary of Aptorum Group Limited. Claves focuses on the clinical development of therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the modulation of gut microbiota-derived metabolites, for the prevention or treatment of diseases. Claves is also exploring a gut microbiota modulation platform that can generate novel customized candidates capable of fine-tuning levels of gut metabolites, potentially treating a wide range of medical conditions.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited Partnership, SMTPH Limited and its subsidiaries. The Smart Pharma Group is wholly owned by Aptorum Group Limited. Smart Pharma Group focuses on systematically repurposing existing approved drugs for the treatment of a large array of orphan diseases. Smart Pharma Group conducts both computational based screening and preclinical validations in advancing the development of its repurposed candidates.
For more information about Smart Pharma Group, please visit www.smtph.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
1 Protein Cell. May; 9(5): 397–403.
2 Obes Surg. 2012 Jun;22(6):956-66
Tel: +852 2117 6611
Tel: + 852 2117 6611
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GSMA: ICT Industry Agrees Landmark Science-based Pathway to Reach Net Zero Emissions27.2.2020 11:30:00 EET | Press release
The ICT industry is today taking an unprecedented step forward in tackling climate change with the release of the first-ever science-based pathway to reduce Greenhouse Gas (GHG) emissions across the telecoms sector. This supports the GSMA’s commitment to helping the mobile industry achieve Net Zero carbon emissions by 2050. The new Science-Based Target (SBT) is the result of a collaboration between the ITU, GeSI, the GSMA, and SBTi to develop a sector-specific decarbonisation pathway that allows ICT companies to set targets in line with the latest climate science. It includes emissions reductions trajectories for mobile, fixed and data centre operators to meet the ambitious Paris Agreement goal of limiting global warming to 1.5°c, designed to substantially reduce the risks and effects of climate change. Twenty nine operator groups representing 30 per cent of global mobile connections are already committed to SBTs. These include America Movil, AT&T, BT, Bharti Airtel, Deutsche Telekom,
KA Imaging’s X-ray Detector Allows Any X-ray System to Be Upgraded to Dual-Energy27.2.2020 11:00:00 EET | Press release
Canadian manufacturer KA Imaging is preparing to launch Reveal, a premium x-ray detector that upgrades any x-ray system to Dual-Energy. “Reveal is the ideal retrofit solution as it will fit into any ISO standard size tray”, explains Amol Karnick, president and CEO of KA Imaging. Thanks to this feature, the cost of implementation can be reduced to a fraction of the price: whereas conventional dual exposure dual-energy systems can cost as high as half a million dollars, KA Imaging’s Reveal can be obtained at a quarter of this price. “You can simply replace your old detector with Reveal, as it will work with any conventional portable or fixed x-ray source”, continues Amol. The competitive pricing strategy is just one of the advantages. KAI developed a unique technology that can improve dual-energy x-ray images. Reveal is the world’s first portable digital detector capable of separating different energy levels with a single exposure. It delivers three images: traditional DR, soft tissue an
The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss27.2.2020 11:00:00 EET | Press release
GN Hearing, the innovation leader in hearing aid technology, today launches a range of exciting new ReSound hearing aid solutions, a move which is in line with the company’s continuous strategic focus on innovation leadership, as communicated as part of the strategy for 2020 and beyond. No matter the degree of hearing loss, the new solutions aim to solve the key listening challenges of people with hearing loss where and when they need it most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005323/en/ (Photo: Business Wire) Globally, 466 million people have a disabling hearing lossii. GN Hearing wants to help every person with hearing loss improve their hearing and live each day to the full. This extensive launch testifies to GN Hearing’s innovation leadership and dedication to helping people with all types of hearing loss, thanks to its leading sound quality, connectivity and customer care. “We are now taking the first
Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation27.2.2020 10:50:00 EET | Press release
Orange, one of the world’s leading multi-service telecommunications operators and present in 18 countries in Africa, will be the first telco to adopt the ground-breaking O3b mPOWER, SES’s next-generation Medium Earth Orbit (MEO) satellite communications system, to exponentially ramp up its consumer and business services, starting in the Central African Republic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226006105/en/ Orange and SES Team up on O3b mPOWER Communications System and Open a New Era for Satellite Connectivity Innovation (Photo: Business Wire) O3b mPOWER is the world’s only fully-funded non-geostationary orbit (NGSO) broadband system in development today. Positioned at only 8,000 kilometres away from Earth, the system will power low-latency high-throughput solutions that can be seamlessly integrated into existing terrestrial networks. When operational in 2022, O3b mPOWER will provide multiple terabits of th
NXP Semiconductors Expands Global Use of the Workiva Platform to Gain Efficiencies and Reduce Risk27.2.2020 10:00:00 EET | Press release
Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announces that Netherlands-based NXP Semiconductors uses the Workiva platform to streamline filings with the U.S. Securities and Exchange Commission and to modernize its Sarbanes Oxley Act (SOX) processes. “We use the Workiva platform to save time in our reporting processes and create efficiencies across our entire finance organization,” said Bryan Moiles, Assistant Corporate Controller at NXP. “We have teams in the Netherlands and the U.S., and the Workiva platform is the only solution that allows me to run a 24-hour clock where I don't have to worry about version control.” With Workiva, Moiles and his team create automatic updates, track every change and seamlessly collaborate with colleagues around the world in real time to create trusted reports and regulatory filings. “The Workiva platform is our one source of truth for all our reports,” said Moiles. “Because everything is linked
DSB to Divest Spare Part Workshops27.2.2020 10:00:00 EET | Press release
Due to structural changes DSB is investigating the market with a view to divesting the activities at the workshops which deliver and maintain spare parts for the trains. Until 2030, Fremtidens Tog (Future Trains) will gradually replace the train sets that DSB is currently operating. This implies that DSB will no longer have the same need to operate its own spare part workshops. Besides, DSB’s coming generation of electric train sets, Fremtidens Tog, are to be maintained by the train supplier and not by DSB, meaning that DSB will have fewer options to redeploy staff from the spare part workshops. Therefore DSB is now transferring the areas of Supply, Logistics & Refurbishment to an independent company to investigate a divestment to a private third party in collaboration with SEB Corporate Finance. As part of this potential transaction, DSB will enter into an agreement with the divested company for delivery and maintenance of spare parts until 2024 with an extension option. As an indepen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom